Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Cash from Operations (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Cash from Operations for 11 consecutive years, with 26732000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations changed N/A to 26732000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 48623171.0, a N/A change, with the full-year FY2025 number at 71532000.0, down 130.01% from a year prior.
  • Cash from Operations was 26732000.0 for Q4 2025 at Crescent Biopharma, down from 16791171.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 5100000.0 in Q1 2025 to a low of 26732000.0 in Q4 2025.
  • A 5-year average of 12372432.56 and a median of 12206712.0 in 2021 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: crashed 303.56% in 2021, then soared 57.03% in 2023.
  • Crescent Biopharma's Cash from Operations stood at 12806565.0 in 2021, then surged by 38.22% to 7911569.0 in 2022, then increased by 3.75% to 7614997.0 in 2023, then plummeted by 38.0% to 10508829.0 in 2024, then plummeted by 154.38% to 26732000.0 in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Cash from Operations are 26732000.0 (Q4 2025), 16791171.0 (Q2 2025), and 5100000.0 (Q1 2025).